NuPathe clears new path to US approval of migraine patch with job and cost cuts
This article was originally published in Scrip
With potential US FDA approval for its first marketed drug on the horizon, NuPathe has disclosed a cost-cutting strategy in documents filed with the US Securities and Exchange Commission (SEC) that includes a 50% workforce reduction and decreased expenditures related to commercialisation of the company's transdermal sumatriptan migraine patch product NP101.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.